Latest From OxiGene Inc.
A JAMA editorial asks whether mergers of academic institutions with non-academic health providers could undermine the perceived value of medical research.
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recent executive-level company changes and promotions in the biopharma, medical device, and diagnostics industries.
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- OxiGene Inc.
- Senior Management
David J Chaplin, PhD, Pres. & CEO
Matthew M Loar, CFO
- Contact Info
Phone: (650) 635-7000
701 Gateway Blvd.
South San Francisco, CA 94080
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.